1. Medtech Insight

AACR-ROUND-UP: A Novel Drug Delivery System And More Liquid Biopsy Results Highlight New Orleans Meeting

Highlights from the American Association for Cancer Research (AACR) Annual Meeting on April 19 include an implantable microdevice for evaluating drug efficacy in treating breast cancer tumors, as well as the latest research and innovation in liquid biopsy testing.

Researchers at MIT and start-up Kibur Medical have developed a microdevice that can be implanted into a breast cancer tumor to identify the best drug to treat that tumor, according to preclinical research presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans on April 19.

Oliver Jonas and Michael Cima, from the Massachusetts Institute of Technology have engineered a plastic cylinder 1mm wide and about 4mm long with multiple drug reservoirs that can be implanted into a tumor with a small biopsy needle

More from Europe

More from Geography

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany

 
• By Ashley Yeo

Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.